We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The most recent trading session ended with McKesson (MCK - Free Report) standing at $672.99, reflecting a +0.74% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%. Meanwhile, the Dow gained 1.01%, and the Nasdaq, a tech-heavy index, lost 0.14%.
The prescription drug distributor's shares have seen an increase of 4.34% over the last month, surpassing the Medical sector's loss of 3.93% and the S&P 500's loss of 6.22%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. The company is expected to report EPS of $9.81, up 58.74% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $93.69 billion, reflecting a 22.7% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $32.76 per share and revenue of $360.63 billion, which would represent changes of +19.39% and +16.73%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. McKesson presently features a Zacks Rank of #3 (Hold).
In terms of valuation, McKesson is presently being traded at a Forward P/E ratio of 20.39. This expresses a premium compared to the average Forward P/E of 16.56 of its industry.
One should further note that MCK currently holds a PEG ratio of 1.43. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.8.
The Medical - Dental Supplies industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Laps the Stock Market: Here's Why
The most recent trading session ended with McKesson (MCK - Free Report) standing at $672.99, reflecting a +0.74% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%. Meanwhile, the Dow gained 1.01%, and the Nasdaq, a tech-heavy index, lost 0.14%.
The prescription drug distributor's shares have seen an increase of 4.34% over the last month, surpassing the Medical sector's loss of 3.93% and the S&P 500's loss of 6.22%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. The company is expected to report EPS of $9.81, up 58.74% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $93.69 billion, reflecting a 22.7% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $32.76 per share and revenue of $360.63 billion, which would represent changes of +19.39% and +16.73%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. McKesson presently features a Zacks Rank of #3 (Hold).
In terms of valuation, McKesson is presently being traded at a Forward P/E ratio of 20.39. This expresses a premium compared to the average Forward P/E of 16.56 of its industry.
One should further note that MCK currently holds a PEG ratio of 1.43. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.8.
The Medical - Dental Supplies industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.